Latest news


Partners4Access runs for International Rare Diseases Day

Sophie Schmitz, Managing Director of Partners4Access participated in an international run to raise money and awareness on International Rare Diseases Day (28th February 2017). The run was in support of Sanofi Genzyme’s campaign. Sophie completed a 12km run this morning along a route that followed the scenic environs of the river Rhine.  Sophie’s achievement will […]

Read More


Hot topics in pharma and orphan drugs

I attended this year’s pharma pricing and market access conference in London with attendees across the pharmaceutical industry, payer and HTA bodies and patient representatives. While following the talks, panel discussions and roundtable debates, a few overarching key topics crystallised: –          Germany – AMNOG changes AMNOG, the German pharmaceutical law is regularly adapted to changes […]

Read More


Patners4Access sponsor this year’s Hilversum Rotary Santa Run

Partners4Access sponsors this year’s Hilversum Rotary Club Santa Run taking place on 17 December. Sophie Schmitz, the Managing Director, participates to raise awareness for kidney diseases. The run supports 2 key charities: the Dutch Kidney Foundation and Toy Donations for Underprivileged Children. The Dutch Kidney Foundation helps patients with kidney diseases and their relatives in […]

Read More


Partners4Access represented at World Orphan Drug Congress

 The World Orphan Drug Congress in Brussels in November was the another conference Partners4Access attended. This year’s agenda focused on the challenges orphan drug manufacturers are facing in the regulatory and HTA environment. Topics as “value for money of orphan medicines” is a challenge our clients are facing every day. High profile health economists discussed […]

Read More


Partners4Access represented at ISPOR

Partners4Access was part of this year’s ISPOR conference in Vienna where payers, manufacturers, regulators and politicians met. High profile speakers from national, regional and global bodies discussed different pricing models for pharmaceuticals, their feasibility and importance to create sustainable and fair health systems. Striving towards a fair health system is closely linked to another key […]

Read More


AMNOG and the German Reforms: What Will Change?

Germany is typically prioritized by the pharmaceutical industry: it remains a market with relatively high drug prices, offers extensive commercial opportunities and has an important position as an international reference country to 17 markets. The implementation of AMNOG in 2011 sought to reduce drug prices and relieve the healthcare budget, yet financial pressure remains, particularly […]

Read More


Partners4Access is pleased to announce the addition of Jose Luis Betrian to the executive team

Executive team strengthened to drive further launch support for the biotechnology industry. Continued focus is ‘Orphan Drug Solutions’ a partnership approach to ensuring a successful global launch. Partners4Access, the global access experts for orphan drugs, has strengthened its executive team this week with the addition of Jose Luis Betrian. Jose Luis joins as Executive Director, […]

Read More